Q32 Bio Inc. $QTTB Shares Bought by Monaco Asset Management SAM

Monaco Asset Management SAM raised its stake in Q32 Bio Inc. (NASDAQ:QTTB) by 17.1% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 591,937 shares of the company’s stock after purchasing an additional 86,486 shares during the period. Monaco Asset Management SAM owned 4.85% of Q32 Bio worth $882,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the stock. Acadian Asset Management LLC acquired a new position in Q32 Bio in the first quarter worth about $50,000. AQR Capital Management LLC bought a new position in Q32 Bio during the 1st quarter worth approximately $68,000. Goldman Sachs Group Inc. grew its position in shares of Q32 Bio by 140.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 44,373 shares of the company’s stock worth $73,000 after acquiring an additional 25,953 shares in the last quarter. Finally, Nuveen LLC acquired a new position in shares of Q32 Bio in the 1st quarter worth approximately $92,000. Institutional investors and hedge funds own 31.32% of the company’s stock.

Q32 Bio Price Performance

Shares of NASDAQ QTTB opened at $2.26 on Friday. The firm has a market capitalization of $27.57 million, a PE ratio of -0.53 and a beta of 0.15. Q32 Bio Inc. has a 1-year low of $1.35 and a 1-year high of $48.65. The business’s fifty day moving average price is $2.38 and its two-hundred day moving average price is $2.01.

Q32 Bio (NASDAQ:QTTB) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.14) by $0.36. Equities research analysts expect that Q32 Bio Inc. will post -12.32 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently issued reports on QTTB. Weiss Ratings reissued a “sell (d-)” rating on shares of Q32 Bio in a research report on Tuesday, October 14th. Wall Street Zen upgraded shares of Q32 Bio from a “sell” rating to a “hold” rating in a research note on Sunday, October 26th. Two research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $12.17.

Q32 Bio Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.